Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT) (EchoCRT)

This study has been terminated.
Sponsor:
Collaborator:
University of Zurich
Information provided by (Responsible Party):
Biotronik, Inc.
ClinicalTrials.gov Identifier:
NCT00683696
First received: August 30, 2007
Last updated: April 17, 2014
Last verified: April 2014
Results First Received: March 12, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Heart Failure
Ventricular Dyssynchrony
Intervention: Device: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Baseline characterisics were analzed for the randomized population.

Reporting Groups
  Description
CRT=ON Cardiac Resynchronization Therapy activated.
CRT=OFF Cardiac Resynchronization Therapy deactivated.
Total Total of all reporting groups

Baseline Measures
   CRT=ON   CRT=OFF   Total 
Overall Participants Analyzed 
[Units: Participants]
 404   405   809 
Age 
[Units: Years]
Mean (Standard Deviation)
 57.6  (12.9)   58.3  (12.6)   58.0  (12.7) 
Gender 
[Units: Participants]
     
Female   110   114   224 
Male   294   291   585 
Region of Enrollment 
[Units: Participants]
     
Portugal   4   3   7 
United States   196   198   394 
Spain   18   18   36 
Austria   6   8   14 
Israel   18   16   34 
United Kingdom   19   18   37 
Switzerland   11   11   22 
Italy   4   4   8 
France   10   11   21 
Czech Republic   12   11   23 
Canada   13   14   27 
Poland   0   2   2 
Belgium   6   6   12 
Australia   12   11   23 
Denmark   24   23   47 
Germany   41   41   82 
Netherlands   10   10   20 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Composite Primary Endpoint: Number of Subjects With First Hospitalization for Worsening Heart Failure or Death   [ Time Frame: From date of randomization until date of death from any cause or date of first hospitalization for worsening heart failure, whichever came first, assessed up to date of study exit, with a mean treatment duration of 1.6 years ]

2.  Primary:   Number of Subjects That Underwent Implant Attempt Without System- or Implant-Related Complications (Complication-Free)   [ Time Frame: 6 months ]

3.  Secondary:   Rate of Worsening Heart Failure Hospitalization (Hospitalizations Per Subject-year)   [ Time Frame: Study duration from randomization to study exit ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

4.  Secondary:   NYHA Classification Change   [ Time Frame: 6 months ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

5.  Secondary:   Change in Quality of Life Scores From Baseline to 6-Month Follow-up   [ Time Frame: 6 months ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

6.  Secondary:   Composite Score of Death, Hospitalization for Worsening Heart Failure and Change in Quality of Life   [ Time Frame: Study duration from randomization to study exit for death, 24 months for hospitalization, 6 months for QOL evaluation ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

7.  Secondary:   Number of Subjects With All-cause Mortality   [ Time Frame: Study duration from randomization to study exit ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Endpoint results should be interpreted with caution and take into consideration the early study closure and subsequent reduction in sample size (809 vs. 1258) and events (218 vs. 381). These changes impact the statistical power of the findings.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Kelly Mohr
Organization: Biotronik, Inc.
phone: 800-547-0394
e-mail: kelly.mohr@biotronik.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Biotronik, Inc.
ClinicalTrials.gov Identifier: NCT00683696     History of Changes
Other Study ID Numbers: EchoCRT
Study First Received: August 30, 2007
Results First Received: March 12, 2014
Last Updated: April 17, 2014
Health Authority: United States: Food and Drug Administration